It may be the "least safe" but its currently on the market. Would be quite easy to get data from patients who had existing OA before starting this drug and seeing what changes have occurred. I would assume hundreds of thousands (if not more) take this drug so getting data would not be difficult at all.
Also the drug is currently approved and sold to people who take it for long periods of t sometimes take it indefinitely. I would assume that the dosage for OA would not be indefinite. Also there are many drugs that have side effects and they are considered before taking them by the doctor and patient. If someone had severe and painful OA, I am sure most would take this if this gave them some form of relief.
research reports and media, page-1269
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.015(6.67%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.0¢ | 22.5¢ | $173.6K | 743.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 99346 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 131244 | 5 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |